跳至主要内容
临床试验/NCT01920607
NCT01920607暂停不适用

Medical and Economic Evaluation of a Magnetic Anal Sphincter for Patients With Severe Anal Incontinence

Nantes University Hospital2 个研究点 分布在 1 个国家目标入组 71 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
不适用
状态
暂停
入组人数
71
试验地点
2
主要终点
Average number of fecal incontinence episodes

研究概览

简要总结

The purpose of this study is to compare 2 surgical treatments of severe fecal incontinence (defined as more than a major leak per week). The hypothesis of this "non-inferiority" trial is that magnetic anal sphincter is clinically as effective as SNS, but more cost-effective in managing fecal incontinence

详细描述

Severe anal incontinence, defined as the uncontrolled passing of stool at least once a week, is a problem that has a serious impact on the quality of life. In the event of failure of conservative treatments, surgery can help improve continence problems in a significant number of cases.

Sacral nerve stimulation is currently the standard surgical treatment for severe anal incontinence when sphincter repair (sphincteroplasty) is not recommended.

A new method of treatment based on sphincter reinforcement through the implanting of a band of magnetic beads*, has proved to be reliable and efficient on a small series of cases, particularly after the failure of sacral nerve stimulation.

The aim of our trial, which compares the "magnetic anal sphincter* and sacral nerve stimulation" in a homogeneous population of patients affected by severe anal incontinence is to define the position of this new approach in the treatment algorithm of this functional disorder, determining its clinical and medical/economic advantages compared to those of the current standard treatment.

* FenixTM (Torax Medical)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patient (male or female) of 18 to 75 years of age
  • Affected by severe anal incontinence (SAI)*.
  • Documented failure of conservative treatment (reeducation and medical treatment)
  • With functional anal sphincter**
  • Agrees to take part in the study and has signed the informed consent form
  • Agrees to undergo post-operative surveillance for a period of one (1) year
  • Covered by National Insurance
  • Defined as follows: at least one involuntary passing of stool per week measured by collecting data on incontinence accidents on a 3-week stool record chart, with the continence problem developing over more than 6 months. **Defined as follows: external sphincter intact (without injury or after sphincter repair) or external sphincter altered, with an injury of a size that does not justify sphincter repair.
  • Internal sphincter injuries not taken into account (by professional consensus).

排除标准

  • Anorectal or pelvic malformations
  • Local conditions incompatible with the proposed sizes of the MAS (extreme obesity, thickness of the tissue in the anorectal area)
  • Sequelae of rectal resections - presence of cancer of the rectum or anus
  • Rectal prolapse and/or major pelvic floor disorders
  • Major chronic disorder of the intestinal motility, irritable bowel syndrome, repeated faecalomas, megarectum
  • Extensive sphincter degeneration
  • Consequences of radiation-induced rectitis and chronic inflammatory diseases of the bowel (Crohn's disease)
  • Neurological disorders or systemic diseases (multiple sclerosis, scleroderma, paraplegia)
  • Festering sores of the perineal and/or anorectal regions
  • Known or suspected risks of allergy to titanium
  • Active pelvic infection
  • Contraindications to SNS:
  • Cardiac stimulator or defibrillator implant
  • Malformation of the sacrum
  • Patient exposed to Magnetic Resonance Imaging
  • Skin diseases exposing the patient to the risk of infection (at the investigator's discretion)
  • Patient scheduled for diathermy or ablation by radiofrequency
  • Pregnant women
  • Adults under guardianship
  • Patients involved in a mobility project in the year following the operation
  • Patient already subjected to one or other of the therapeutic approaches (MAS or SNS) Please note: coagulation problems (including anti-aggregant or anti-coagulant treatments) are not a contraindication if these problems can be corrected during the perioperative period.

结局指标

主要结局

Average number of fecal incontinence episodes

时间窗: 6 months

Average number of fecal incontinence episodes per week over a period of 3 weeks, 6 months after the implantation of a magnetic anal sphincter (FenixTM magnetic anal sphincter group) or of the Spinelli electrode during the PNE test (sacral nerve stimulation group), on the basis of a standardised stool diary

次要结局

  • Overall cost for the health care system(12 months)
  • Respective complications of the two therapeutic approaches(12 months)
  • Functional results at 6 and 12 months, compared with baseline(Baseline, 6 & 12 months)
  • Quality of life and overall satisfaction(Baselnie, 6 & 12 months)
  • Anorectal manometry data(Baseline & 6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验